One was placed in the laboratory of Dr. Radoslav Goldman of Georgetown University, while the other was installed in the lab of a leading biotech company, according to Pressure BioSciences' statement.
The company launched the benchtop Barozyme HT48 in June, which uses disposable and automated microwell strips that are used by labs worldwide, a huge change from its previous instruments which required individual test tubes and handling samples manually.
The benefit of the automated strips is that they can be left unattended, which has been seen by analysts as the biggest drawback from switching to PCT-based instruments until recently.
The company's pressure cycling technology, on which its products are based, is used for genomic, proteomic and small molecule sample preparation, among multiple applications in the estimated $6 billion life sciences sample preparation market. PCT has been proven to increase proficiencies in biological sample preparation, and works by cycling pressure between ambient and ultra-high levels at controlled temperatures to control the interactions of bio-molecules.
Pressure BioSciences said Tuesday that it believes its new systems will deliver "important and unique capabilities" for the analysis and characterization of biological samples in both settings.
Both groups are current customers of the company's patented PCT-based products, it added.
The Barozyme HT-48, which was designed for rapid protein digestion, is capable of processing up to 48 samples simultaneously using its BaroFlex 8-well, single-use processing strips.
"We are delighted to have the first two independent evaluations of the Barozyme HT48 System being conducted by such well-regarded, important groups," said VP of marketing and sales for Pressure BioSciences, Dr. Nate Lawrence.
"We expect to complete the assembly, release, and shipment of the next three Barozyme HT48 Systems within the coming weeks and to install them shortly thereafter.
"Many groups have asked or agreed to be included in the Barozyme HT48 System evaluation program, including world renowned pharmaceutical, biotechnology, academic, government, and commercial testing laboratories. We believe these evaluations will fuel growth, increase revenue for existing and new PCT-based applications and products, and greatly facilitate the formation of new strategic partnerships."
Dr. Goldman of Georgetown University added that he believes the new Barozyme system has the potential to offer accelerated, higher quality sample preparation, which may bring "measurable benefits" to biomarker discovery for cancer and other diseases.